FDA Awards Lilly’s Olaratumab Priority Review

The FDA has granted priority review to Eli Lilly’s combination-candidate olaratumab and doxorubicin for treatment of advanced soft tissue sarcoma that does not respond to radiotherapy or surgery.

Olaratumab already has received breakthrough therapy, fast track and orphan drug-status for the same indication.

The FDA’s decision was based on a Phase 2 trial that compared the olaratumab/doxorubicin combination to doxorubicin alone.